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Abstract 
Heparin is an anticoagulant medicinally used to inhibit blood clotting.  It is commonly 
administered to patients requiring surgery or kidney dialysis.  Presently, it is produced 
from animal tissues, but a recent contamination crisis pointed to the need for a safer 
source of the drug.  Our project seeks to develop a rapid, inexpensive, high-throughput 
assay to quantitate the production of heparin and other glycosaminoglycans (GAGs) from 
cultured mammalian cells.  In order to quantitate heparin from cell culture media, a 
purification method is needed to separate GAGs from interfering constituents in the 
media.  We developed a purification protocol that absorbs Pluronic and most proteins to 
Sep-Pak C-18 cartridges, followed by ultrafiltration through 5 kDa cutoff Vivaspin 
centrifugal concentrators.  The purified GAGs are then quantitated by a microcarbazole 
assay.  
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 4 
Introduction 
Heparin is a highly sulfated glycosaminoglycan (GAG) composed of repeating 
disaccharides of L-iduronic acid or D-glucuronic acid and N-acetyl-D-glucosamine¹.  It is 
a hydrophilic molecule with the highest negative charge density among all known 
biological molecules² and contains chains with molecular weights ranging from 6,000 to 
30,000 Daltons³. 
Heparin is one of the most widely used anticoagulants in the pharmaceutical 
industry¹.  Currently, it is extracted from animal tissues, including porcine intestines and 
bovine lungs⁴.  A health crisis in 2008 from contamination caused by an oversulfated 
chondroitin sulfate⁵ led to approximately 100 deaths in the United States², pointing to 
the need for a safer source of heparin.  
One goal of the Sharfstein lab is to metabolically engineer Chinese hamster ovary 
(CHO) cells to produce heparin⁴.  CHO cells are capable of producing heparan sulfate 
(HS), a less sulfated form of heparin, naturally⁴.  Since heparin and HS form a family of 
GAGs that share the same biosynthetic pathway⁶ , CHO cells present a possible new 
source of heparin.  As part of this endeavor, a GAG purification method was previously 
established to isolate and concentrate GAGs⁴, as well as prevent interference from other 
components of culture media during the subsequent quantitation step using the 
microcarbazole assay, which detects the concentration of the purified GAGs⁷ .  
Carbazole-based quantification utilizes sodium tetraborate in sulfuric acid to hydrolyze 
the GAGs into uronic acid and glycosamine⁷.  Carbazole subsequently reacts with the 
uronic acid, yielding a colored product that can be quantitated spectrophotometrically⁷.  
The current purification protocol is costly both in time and materials⁴.  Thus, our project 
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seeks to develop a rapid, inexpensive, high-throughput assay to purify and quantitate the 
production of heparin and other glycosaminoglycans (GAGs) from cultured mammalian 
cells.   
 There are two key components of cell culture media that interfere with the 
microcarbazole assay whose characteristics we focus on to build our new protocol, 
Pluronic and glucose. 
First, Pluronic F68 is used in cell culture as an anti-foaming agent and to protect 
cell membranes from shearing⁸.  Pluronic F68 is a poloxam er and contains a hydrophilic 
poly(ethylene oxide) and hydrophobic poly(propylene oxide)⁹.  Thus, to rem ove 
Pluronic and other hydrophobic contaminants, we employ liquid chromatography using 
Waters Sep-Pak C-18 classic cartridges, which utilize a strongly hydrophobic silica-based 
bonded phase¹⁰.   
Second, glucose is added to cell culture systems to act as a primary source of fuel 
for animal cells, which are heterotrophs who obtain energy from coupled oxidation-
reduction reactions¹¹.  Glucose is a strongly hydrophilic hexose sugar¹² with a molecular 
weight of 180 Da.  Thus, to remove glucose and other small interfering molecules, we 
employ ultrafiltration using Sartorius Vivaspin centrifugal concentrators, which utilize a 
semi-permeable membrane to separate solutions based on size¹³.  
Our hypothesis is that the new GAG purification protocol utilizing liquid 
chromatography and ultrafiltration can achieve its purpose of heparin and GAG isolation 
while greatly reducing the time and cost required to run the experiments. 
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Materials & Methods 
Sodium heparin (lot #SLBL6351V) was from Sigma-Aldrich.  Sep-Pak C-18 classic 
cartridges (WAT051910) were from Waters.  Vivaspin 6 (3 kDa cutoff) (lot 
#1703005VS) and Vivaspin 15R (5 kDa cutoff) (lot #1701014VS) centrifugal 
concentrators were from Sartorius.  A Thermo Scientific 8 x 50 mL fixed angle rotor was 
used for all centrifugations. 
 
A.  Microcarbazole Assay¹⁴ 
To quantitate the concentration of heparin, the colorimetric microcarbazole assay was 
employed.  Two separate revisions of the microcarbazole assay were used. 
 
Revised Microcarbazole Assay #1 
A revised assay was developed to reduce the time required by combining the two heating 
steps and separate addition of reagents into one.  Additionally, sulfamide was used to 
react with some of the byproducts that give false color.  Twenty five-µL samples were 
added to a Thermo Scientific PCR plate.  2.5-µL of 4M sulfamide was added, as well as 
175 µL of reagent A (2-mL of 1.25 M sodium tetraborate decahydrate in hot water and 
98-mL of 99% sulfuric acid) to hydrolyze and dehydrate the uronic acid of heparin into 
furans, and 5 µL of reagent B (1.25 g/L carbazole in absolute ethanol) to react the furans 
with carbazole to form a colored compound.  The plate was covered with a plastic film 
and heated in the thermal cycler at 100ºC for 15 minutes to enable the hydrolysis and 
carbazole reactions, followed by chilling to 4°C.  150 µL of each sample was transferred 
to a Costar 96-well plate and the absorbance was measured at 525 nm using a Fisher 
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Scientific microplate reader (instrument: Infinite 200, equipment number: 10294608) and 
Tecan i-control application.   
 
Heparin Standard Curve Using Revised Microcarbazole Assay #1 
To test the effectiveness of the revised microcarbazole assay #1, a 1 mg/mL heparin 
solution was used to create a standard curve.  The sample concentrations used were 0, 
0.5, 5, 10, and 20 µg/25 µL sample.  
 
Revised Microcarbazole Assay #2  
A second revised assay using a lower reaction temperature was developed to reduce the 
effects of a high temperature, such as charring that produces false color.  Additionally, to 
reduce the propagation of pipetting errors, an Eppendorf Repeater M4 Manual Handheld 
Pipette Dispenser was used to add all reagents (using 0.1 mL pipette tips for sulfamide 
and reagent B and 5 mL tips for reagent A), and the 25-µL samples were added directly 
to the 96-well plate.  The repeater pipette was used to add 2-µL of 4M sulfamic acid, 5 
µL of reagent B, and 150 µL of reagent A.  The plate was then incubated on a hot plate at 
60°C for 1 hour (a study of different heating times was conducted and 1 hour was chosen 
as optimal).  The absorbance was measured at 525 nm using a Fisher Scientific 
microplate reader and Tecan i-control application. 
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Heparin Standard Curve Using Revised Microcarbazole Assay #2 
To test the effectiveness of revised microcarbazole assay #2, a 1 mg/mL heparin solution 
was used to create a standard curve.  The sample concentrations used were 0, 2, 2.5, 5, 
10, 15, 20, and 25 µg/25 µL sample.  
 
Heparin Standard Curve with Repeater Pipette Using Revised Microcarbazole Assay #2  
To increase the accuracy of the standard curve, a repeater pipette was used to create the 
standard curve using a 1 mg/mL heparin solution.  The sample concentrations used were 
0, 5, 10, 15, 20, 22, and 24 µg/25 µL sample.  
 
B.  Liquid Chromatography Using Waters Sep-Pak C-18 Classic Cartridges 
To remove Pluronic F68 in solution, liquid chromatography experiments were performed 
using Waters Sep-Pak C-18 classic cartridges. 
 
Using Sep-Pak C-18 Classic Cartridges 
The Sep-Pak C-18 cartridge was washed using a syringe with 5 mL of ethanol and 2 x 5 
mL of water.  The sample was then passed through the cartridge, followed by one 1-mL 
water wash. 
 
Removing Pluronic in Solution 
Two-mL of a 10 mg/mL solution of Sigma-Aldrich Pluronic F68 was passed through one 
Sep-Pak C-18 cartridge prepared as described above (but followed by two water washes 
to maximize recovery) with the objective of retaining the Pluronic in the column.  The 
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flow-through and washes were placed in a pre-weighed 15 mL conical centrifuge tube, 
frozen, lyophilized, and reweighed to determine how much Pluronic did not adsorb to the 
C-18 resin. 
 
C.  Ultrafiltration Using Sartorius Vivaspin 6 Centrifugal Concentrators 
To test the ability of the Vivaspin centrifugal concentrators to retain heparin and remove 
glucose from the solution, ultrafiltration experiments were conducted using Sartorius 
Vivaspin 6 centrifugal concentrators. 
 
Retaining Heparin in Solution 
Six-mL of a 2 mg/mL heparin solution was added to a Vivaspin 6 centrifugal 
concentrator and two 25-µL samples were reserved.  The filter was centrifuged at 10,000 
x g at 18ºC for 45 minutes and two 25-µL samples of the permeate were reserved.  Six 
mL of water was added to the retentate and two 25-µL samples were reserved.  The 
centrifugal concentrator was then centrifuged once more and the samples reserved as 
before.  All samples were transferred into a PCR plate and analyzed by the revised 
microcarbazole assay #1.   
 
Removing Glucose in Solution 
Six-mL of a 0.1% glucose solution was added to a Vivaspin 6 centrifugal concentrator 
and two 25-µL samples were reserved.  The filter was centrifuged at 10,000 x g at 18ºC 
for 45 minutes and two 25-µL samples of the permeate were reserved.  Six mL of water 
was added to the retentate before two 25-µL samples were reserved.  The centrifugal 
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concentrator was then centrifuged once more and the samples reserved as before.  All 
samples were transferred into a PCR plate and analyzed by the revised microcarbazole 
assay #1. 
 
D. GAG Purification Experiments Using Ultrafiltration with Sartorius Vivaspin 15R 
Centrifugal Concentrators & Liquid Chromatography with Waters Sep-Pak C-18 
Classic Cartridges 
To determine if heparin could be isolated in various larger solutions, GAG purification 
experiments were performed using liquid chromatography with Waters Sep-Pak C-18 
classic cartridges and ultrafiltration with Sartorius Vivaspin 15R centrifugal 
concentrators. 
 
Isolating Heparin from Pluronic and Glucose in Solution 
In one conical tube, 4 mL of nanopure water was added to 1-mL of a 2 mg/mL heparin 
solution.  100 mg of glucose (a higher concentration was used to better see any residual 
glucose after spins) and 100 mg of Pluronic F68 was added to 10 mL of water, and 4-mL 
of the Pluronic-glucose solution was added to a second conical tube containing 1-mL of a 
2 mg/mL heparin solution.  Three 25-µL samples were reserved from both conical tubes.  
Both solutions were passed through three Sep-Pak C-18 cartridges prepared as described 
above, and three 25-µL samples were reserved from the total eluent.  The solutions were 
then each placed in a Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x g 
at 18ºC for 45 minutes, and three 25-µL samples were reserved from the permeate.  Ten 
mL of water was added to the retentate before three 25-µL samples were taken.  The 
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centrifugal concentrator was then centrifuged twice more and the samples reserved as 
before.  All samples were transferred into a 96-well plate and analyzed by the revised 
microcarbazole assay #2. 
 
Isolating Heparin from Interfering Components in Fresh Medium 
In one conical tube, 4 mL of nanopure water was added to 1-mL of a 2 mg/mL heparin 
solution.  In a second conical tube, 4 mL of medium was added to 1-mL of a 2 mg/mL 
heparin solution.  In a third conical tube, 4 mL of medium was added to 1 mL of 
nanopure water.  Three 25-µL samples were reserved from each tube.  All three solutions 
were passed through three Sep-Pak C-18 cartridges prepared as described above, and 
three 25-µL samples were reserved from the total eluent.  The solutions were then each 
placed in a Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x g at 18ºC 
for 45 minutes, and three 25-µL samples were reserved from the permeate.  Ten mL of 
water was added to the retentate before three 25-µL samples were taken.  The centrifugal 
concentrator was then centrifuged twice more and the samples reserved as before.  All 
samples were transferred into a 96-well plate and analyzed by the revised microcarbazole 
assay #2. 
 
Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Samples  
Eight mL of conditioned medium sample (names are specified in Table 1) was added to a 
conical tube and three 25-µL samples were reserved.  The samples were purified using a 
Sep-Pak C-18 cartridge, and three 25-µL samples were reserved.  This larger-volume 
sample was added to a Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x 
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g at 18ºC (centrifugation times specified in Table 1).  The centrifugations were repeated 
twice more.  After each centrifugation, three 25-µL samples were reserved from the 
permeate and 10 mL of water added to the retentate (except for the final retentate, which 
was filled to the volume indicated in Table 1) before three 25-µL samples were reserved.  
Upon exploring various centrifugation times, 45 minutes was determined to be optimal 
when the tip of the membrane was properly oriented towards the center of the centrifuge.  
All samples were transferred into a 96-well plate and analyzed by the revised 
microcarbazole assay #2. 
 
Table 1: Specifications of the medium sample name, time for each centrifugation, and 
amount of water added to the final retentate before samples were taken from experiment 
of the recovery of heparin-like glycosaminoglycans from conditioned medium samples. 
Name of Medium Sample Used Centrifugation Time 
(Minutes) 
Water Added to 
Final Retentate (mL) 
C5 Epi 11/2/17 3rd fed Batch = 50 mL 75 0.5 
C5 Epi 2 mM B 7/13/17 45 10 
C5 Epi 4 mM C 7/18/17 110 10 
 
E.  Comparing Old GAG Purification Method & New GAG Purification Method 
To compare the recovery of heparin-like glycosaminoglycans from conditioned media 
samples, the old GAG purification method⁴ and new GAG purification method (liquid 
chromatography using Sep-Pak C-18 classic cartridges and ultrafiltration using Vivaspin 
15R centrifugal concentrators) were performed three times each using the same 
conditioned media sample (combined ChS Excell A 8/20/17 and ChS Hycell B 8/19).  
Six 8-mL samples of conditioned media were added to separate conical tubes.  GAGs 
from three of the samples were purified using the original GAG purification method⁴, 
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and the resulting purified GAGs were reserved in separate Eppendorf tubes.  The other 
three samples were purified using the new GAG purification method: solutions were 
passed through three Sep-Pak C-18 cartridges prepared as described above, and three 25-
µL samples were reserved from the total eluent.  The solutions were then each placed in a 
Vivaspin 15R centrifugal concentrator and centrifuged at 10,000 x g at 18ºC for 45 
minutes, and three 25-µL samples were reserved from the permeate.  Ten mL of water 
was added to the retentate before three 25-µL samples were taken.  The centrifugal 
concentrator was then centrifuged twice more and the samples reserved as before with 
one exception: the final retentate alone was transferred to an Eppendorf tube, and 100 µL 
of water was added to the centrifugal concentrator to recover all product, which was also 
transferred to the Eppendorf tube.  Two 25-uL samples of all six experiments were 
transferred into a 96-well plate and analyzed by the revised microcarbazole assay #2. 
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Results 
A.  Microcarbazole Assay 
 
Heparin Standard Curve Using Revised Microcarbazole Assay #1 
To reduce the amount of time required for the microcarbazole assay and the production of 
false color, the two heating steps were combined into one and sulfamide was added to 
prevent false color.  The revised microcarbazole assay #1 was performed to detect the 
concentration of heparin by measuring the absorbance at 525 nm.  In Figure 1, the 
absorbance values of a standard curve that utilizes the revised microcarbazole assay #1 
are reported.  The revised microcarbazole assay #1 was able to accurately quantitate 
heparin in solution. 
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Figure 1: Heparin standard curve using the revised microcarbazole assay #1.  
 
Heparin Standard Curve Using Revised Microcarbazole Assay #2 
To reduce the propagation of pipetting errors and the effects of a high temperature, the 
revised microcarbazole assay #1 was further revised to utilize a repeater pipette to add the 
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reagents, add the samples directly to a 96-well plate, and perform the assay at a lower 
temperature (60°) by using a hot plate instead of a thermal cycler to heat the samples.  
The revised microcarbazole assay #2 was performed in triplicate to detect the 
concentration of heparin by measuring the absorbance at 525 nm.  In Figure 2, the 
absorbance values of a standard curve that utilizes the revised microcarbazole assay #2 
are reported.  The revised microcarbazole assay #2 was able to accurately quantitate 
heparin in solution. 
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Figure 2: Heparin standard curve using a revised microcarbazole assay #2 at various 
heating times.  The revised microcarbazole assay #2 was performed in triplicate.  Error 
bars represent the standard deviation of triplicate measurements of revised 
microcarbazole assay #2. 
 
Heparin Standard Curve with Repeater Pipette Using Revised Microcarbazole Assay #2  
To increase the accuracy of the standard curve using the revised microcarbazole assay #2, 
a repeater pipette was used to add the heparin samples.  The revised microcarbazole assay 
#2 was performed in triplicate to detect the concentration of heparin by measuring the 
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absorbance at 525 nm.  In Figure 3, the absorbance values of the standard curve that 
utilizes a repeater pipette and the revised microcarbazole assay #2 are reported.  The 
repeater pipette was able to improve the quantitation of heparin using the revised 
microcarbazole assay #2. 
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Figure 3: Heparin standard curve with a repeater pipette using the revised 
microcarbazole assay #2 for 1 hour.  The revised microcarbazole assay #2 was performed 
in triplicate.  Error bars represent the standard deviation of triplicate measurements of the 
revised microcarbazole assay #2. 
 
B.  Liquid Chromatography Using Waters Sep-Pak C-18 Classic Cartridges 
 
Removing Pluronic in Solution 
To remove Pluronic from water, a liquid chromatography experiment using Sep-Pak C-18 
classic cartridges, followed by a lyophilization experiment, were conducted.  In Table 2, 
the mass of the conical tube is reported both before (prior to the addition of Pluronic) and 
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after the experiment, as well as the mass of Pluronic added to the conical tube.  The 
cartridges removed all of the starting 2-mL of 10 mg/mL Pluronic. 
 
Table 2: Removal of Pluronic in solution during a liquid chromatography experiment 
using Sep-Pak C-18 classic cartridges and a lyophilization experiment. 
Mass Before Liquid 
Chromatography & 
Lyophilization (g) 
Mass of Pluronic in 
2 mL water (mg) 
 
Mass After Liquid 
Chromatography & 
Lyophilization (g) 
Difference 
(mg) 
 
6.8653 20 6.8653 0 
 
C.  Ultrafiltration Using Sartorius Vivaspin 6 Centrifugal Concentrators 
 
Retaining Heparin in Solution 
To determine if heparin could be retained using centrifugal concentrators, heparin in 
solution was ultrafiltered using Vivaspin 6 centrifugal concentrators.  The revised 
microcarbazole assay #1 was performed in duplicate to detect the concentration of 
heparin by measuring the absorbance at 525 nm.  In Figure 4, concentrations are reported 
as a percentage of the starting absorbance value of heparin.  The filters retained 
approximately all of the starting 6-mL of 2 mg/mL heparin. 
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Figure 4: Recovery of heparin from water during each stage of an ultrafiltration 
experiment using Vivaspin 6 centrifugal concentrators.  The revised microcarbazole 
assay #1 was performed in duplicate. 
 
Removing Glucose in Solution 
To determine if glucose could be removed using centrifugal concentrators, glucose in 
solution was ultrafiltered using Vivaspin 6 centrifugal concentrators.  The revised 
microcarbazole assay #1 was performed in duplicate to detect the concentration of 
glucose by measuring the absorbance at 525 nm.  In Figure 5, concentrations are reported 
as a percentage of the starting absorbance value of glucose.  Although the microcarbazole 
assay is not quantitative for glucose, the filters appeared to remove approximately 96% of 
the starting 6-mL of 0.1% glucose. 
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Figure 5: Removal of glucose from water during each stage of an ultrafiltration 
experiment using Vivaspin 6 centrifugal concentrators.  The revised microcarbazole 
assay #1 was performed in duplicate. 
 
D. GAG Purification Experiments Using Ultrafiltration with Sartorius Vivaspin 15R 
Centrifugal Concentrators & Liquid Chromatography with Waters Sep-Pak C-18 
Classic Cartridges 
 
Isolating Heparin from Pluronic and Glucose in Solution 
To isolate heparin from Pluronic and glucose in solution, a GAG purification experiment 
utilizing liquid chromatography and ultrafiltration was conducted.  Two samples (a 5-mL 
solution of 2 mg/mL of heparin in water and a 5-mL solution of 2 mg/mL of heparin, 10 
mg/mL of glucose, and 10 mg/mL of Pluronic) were purified by liquid chromatography 
using Sep-Pak C-18 cartridges and ultrafiltration using Vivaspin 15R centrifugal 
concentrators.  The revised microcarbazole assay #2 was performed to detect the 
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concentration of heparin by measuring the absorbance at 525 nm.  In Figure 6, 
concentrations are reported as the absorbance units at 525 nm.   
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Figure 6: Recovery of heparin from water or known interfering compounds (Pluronic 
and glucose) during each stage of a GAG purification experiment using liquid 
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R 
centrifugal concentrators.  Error bars represent the standard deviation of triplicate runs of 
the GAG purification experiment. 
 
Isolating Heparin from Interfering Components in Fresh Medium 
To isolate heparin from interfering components in fresh medium, a GAG purification 
experiment utilizing liquid chromatography and ultrafiltration was conducted.  Three 
samples (a 5-mL solution of 2 mg/mL of heparin in water, a 5-mL solution of 2 mg/mL 
of heparin in medium, and a 5-mL solution of 1 mL of medium in water) were purified by 
liquid chromatography using Sep-Pak C-18 cartridges and ultrafiltration using Vivaspin 
15R centrifugal concentrators.  The revised microcarbazole assay #2 was performed to 
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detect the concentration of heparin by measuring the absorbance at 525 nm.  In Figure 7, 
concentrations are reported as the absorbance units at 525 nm.   
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Figure 7: Recovery of heparin from water, heparin from fresh medium, or medium in 
water during each stage of a GAG purification experiment using liquid chromatography 
with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R centrifugal 
concentrators.  Error bars represent the standard deviation of triplicate runs of the GAG 
purification experiment. 
 
Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Sample #1 
To determine how much heparin-like glycosaminoglycans could be recovered from 
conditioned medium sample #1, a GAG purification experiment was conducted using 
liquid chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 
15R centrifugal concentrators.  A sample was not taken after the first centrifugation.  The 
revised microcarbazole assay #2 was performed in triplicate to detect the concentration of 
 22 
heparin by measuring the absorbance at 525 nm.  In Figure 8, concentrations are reported 
as the absorbance units at 525 nm.  The amount recovered was 15.9 µg/mL. 
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Figure 8: Recovery of heparin-like glycosaminoglycans from conditioned medium 
sample #1 during each stage of GAG purification experiment using liquid 
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R 
centrifugal concentrators.  The revised microcarbazole assay #2 was performed in 
triplicate. 
 
Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Sample #2 
To determine how much heparin-like glycosaminoglycans could be recovered from 
conditioned medium sample #2, a GAG purification experiment was conducted using 
liquid chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 
15R centrifugal concentrators.  The revised microcarbazole assay #2 was performed in 
triplicate to detect the concentration of heparin by measuring the absorbance at 525 nm.  
In Figure 9, concentrations are reported as the absorbance units at 525 nm.  The amount 
recovered was 20.6 µg/mL.   
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Figure 9: Recovery of heparin-like glycosaminoglycans from conditioned medium 
sample #2 during each stage of a GAG purification experiment using liquid 
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R 
centrifugal concentrators.  The revised microcarbazole assay #2 was performed in 
triplicate. 
 
Recovery of Heparin-Like Glycosaminoglycans from Conditioned Medium Sample #3 
To determine how much heparin-like glycosaminoglycans could be recovered from 
conditioned medium sample #3, a GAG purification experiment was conducted using 
liquid chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 
15R centrifugal concentrators.  The revised microcarbazole assay #2 was performed in 
triplicate to detect the concentration of heparin by measuring the absorbance at 525 nm.  
In Figure 10, concentrations are reported as the absorbance units at 525 nm.  The amount 
recovered was 10.0 µg/mL.  
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Figure 10: Recovery of heparin-like glycosaminoglycans from conditioned medium 
sample #3 during each stage of a GAG purification experiment using liquid 
chromatography with Sep-Pak C-18 cartridges and ultrafiltration with Vivaspin 15R 
centrifugal concentrators.  The revised microcarbazole assay #2 was performed in 
triplicate. 
 
E.  Comparing Old GAG Purification Method & New GAG Purification Method 
To compare the old and new GAG purification methods, three trials of each protocol 
were performed using the same conditioned media sample.  The revised microcarbazole 
assay #2 was performed in duplicate to determine the concentration of heparin by 
measuring the absorbance at 525 nm.  In Figure 11, the concentrations of the heparin-like 
glycosaminoglycans recovered are reported.  Both protocols were repeatable, and the new 
GAG protocol yielded a higher concentration.  
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Figure 11: Recovery of heparin-like glycosaminoglycans from conditioned media using 
the old and new GAG purification methods.  The revised microcarbazole assay #2 was 
performed in duplicate.  Error bars represent the standard deviation of triplicate runs of 
the GAG purification experiments.   
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Discussion 
We were able to develop a new GAG purification method that utilized liquid 
chromatography using Waters Sep-Pak C-18 classic cartridges and ultrafiltration using 
Sartorius Vivaspin 15R centrifugal concentrators.  Compared to the old GAG purification 
method, the new GAG purification method reduces the required time from 3 days to less 
than 4 hours and the cost from $38.18 to $22.61 per sample (Table 3).   
 
Table 3: The costs per sample to run the old GAG purification method and new GAG 
purification method.  The manufacturer website links are in the appendix. 
New GAG Purification Protocol 
Item Price Whole 
Set ($) 
Items Per 
Set 
Price Per 
Item ($) 
Items 
Needed 
Total 
Price ($) 
Sep-Pak C18 Classic 
Cartridge 
218 50 4.36 3 13.08 
Sartorius Vivaspin 15R 
Centrifugal 
Concentrators 
457.31 48 9.53 1 9.53 
Total Price Per Sample 22.61 
 
Old GAG Purification Protocol 
Item Price Whole 
Set ($) 
Items Per 
Set 
Price Per 
Item ($) 
Items 
Needed 
Total 
Price ($) 
Amicon Ultra-15 
Centrifugal Filter Units 
281 24 11.71 1 11.71 
Syringe Filter, PVDF, 
0.22µm, 30mm 
Diameter, Sterile 
58 30 1.93 1 1.93 
Amicon Ultra-0.5 mL 
Centrifugal Filters 
386 96 4.02 2 8.04 
Sartorius Vivapure Q 
Mini H IEX Spin 
Columns 
198 24 8.25 2 16.50 
Total Price Per Sample 38.18 
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Our study first confirmed that Sep-Pak C-18 cartridges could remove Pluronic 
from solution.  One Sep-Pak was sufficient for the removal of Pluronic alone, but since 
the conditioned medium samples needed 3 Sep-Pak cartridges for the maximum removal 
of color, we used that standard for all our experiments except for the three experiments 
using conditioned medium samples #1, #2, and #3 since these experiments were 
conducted before we determined that 3 Sep-Pak cartridges was optimal. 
We also showed that ultrafiltration with Vivaspin centrifugal concentrators could 
remove almost all the glucose while retaining almost all the heparin in water.  However, 
we observed a large deviation from 100% in the final retentate of the heparin experiment.  
We suggest that this may have resulted from the fact that glucose interferes with the 
microcarbazole assay and can give either diminished or increased absorbance depending 
on the amount of charring that results from the high temperature required by the assay.  
In addition, the microcarbazole assay was found to be prone to contamination from the 
covering film and is more sensitive to errors when pipetting from one plate to another.  
As a result, the microcarbazole assay was revised to a lower temperature using a hot plate 
instead of a thermal cycler to heat the samples.  It was evident from the heparin standard 
curve that this method worked to quantitate the heparin and that one hour, which had the 
most linear curve, was the optimal time.  Further, using a repeater pipette to create the 
standard curve and add the reagents increased the accuracy.  Revising the microcarbazole 
assay also reduced the amount of time required for the microcarbazole assay to one hour. 
We moved forward with the Vivaspin 15R centrifugal concentrators to work with 
larger sample volumes.  Using the new GAG purification method, we were able to isolate 
almost all the heparin from glucose and Pluronic in solution, observing that most 
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interference was removed in the permeate resulting from the Vivaspin centrifugal 
concentrators.  We were also able to isolate heparin from other potentially interfering 
contaminants in fresh medium, again observing the removal of interference following the 
chromatography and ultrafiltration steps.  Medium lacking heparin showed no reaction 
when the retentate was assayed by the microcarbazole assay, showing that the interfering 
compounds were removed in the permeate. 
We then showed that the new GAG purification method recovered varying 
amounts of heparin-like glycosaminoglycans from three different conditioned medium 
samples.  Conditioned medium sample #3 required a longer centrifugation time, 
suggesting that different conditioned medium samples may require varying centrifugation 
times.  We determined that, when the edge of the membrane was oriented towards the 
center of the centrifuge, a 45-minute spin achieved our desired retentate volume below 
0.5 mL, so we decided that 45 minutes was the optimal time for each centrifugation. 
We were then able to determine and compare the amount of heparin-like 
glycosaminoglycans recovered from the old and new GAG purification methods.  We 
found that the new purification method recovered a higher concentration, which we 
presumed was because the old purification method had an anion-exchange step that was 
selective for the most highly charged glycosaminoglycans.  Future work will focus on 
analyzing and comparing the constituents of these samples. 
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Appendix I 
 
Links to the manufacturer websites for each item used in the old GAG purification 
method and new GAG purification method. 
 
 
Old GAG Purification Method 
 
Amicon Ultra-15 Centrifugal Filter Units: 
http://www.emdmillipore.com/US/en/product/Amicon-Ultra-15-Centrifugal-Filter-
Units,MM_NF-C7715#ordering-information 
 
Syringe Filter, PVDF, 0.22µm, 30mm Diameter, Sterile: 
https://www.celltreat.com/syringe-filter-pvdf-022µm-30mm-diameter-sterile 
 
Amicon Ultra-0.5 mL Centrifugal Filters: 
http://www.emdmillipore.com/US/en/product/Amicon-Ultra-0.5nbspmL-Centrifugal-Filters-
for-DNA-and-Protein-Purification-and-Concentration,MM_NF-C82301#ordering-
information 
 
Sartorius Vivapure Q Mini H IEX Spin Columns: 
https://www.fishersci.de/shop/products/sartorius-vivapure-q-mini-h-iex-spin-
columns/11760855 
 
New GAG Purification Method  
 
Sep-Pak C18 Classic Cartridge: 
http://www.waters.com/waters/partDetail.htm?partNumber=WAT051910&xcid=ext5005&gc
lid=Cj0KCQjw2pXXBRD5ARIsAIYoEbfQmx4mNygOawQhD7kj1zZXFITm8T9IBcFrZvg
EvanbESZwuSsU3ZoaAtbXEALw_wcB 
 
Sartorius Vivaspin 15R Centrifugal Concentrators: 
https://www.fishersci.com/shop/products/sartorius-vivaspin-15r-centrifugal-concentrators-
8/p-4187753  
 
 
 
 
